Cargando…
Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
Prolyl hydroxylase (PHD) inhibitors are in clinical development for anaemia in chronic kidney disease. Epidemiological studies have reported conflicting results regarding safety of long-term therapeutic haemoglobin (Hgb) rises through PHD inhibition on risk of cardiovascular disease. Genetic variati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851745/ https://www.ncbi.nlm.nih.gov/pubmed/36048866 http://dx.doi.org/10.1093/hmg/ddac215 |